Wetherby, United Kingdom

Avacta is a UK-based biopharmaceutical company developing novel cancer immunotherapeutics and high performing diagnostics, based on its two proprietary platforms: Affimer and pre|CISION.


Investment Perspective

Avacta is seeking to capitalise on the positive perception shift in the diagnostic market since COVID-19 brought testing to the masses. An M&A-led growth strategy, complemented by internal capabilities, notably the proprietary Affimer platform, should create a self-sustaining Diagnostics business. The acquisition of Launch Diagnostics was the first step, with additional complementary targets being sought and the firepower to execute. Meanwhile in Therapeutics, lead asset AVA6000 continues to progress and should validate the pre|CISION platform’s clinical utility. This remains the biggest near-term value driver. Our updated valuation is £587m, equivalent to 221p/share with potential upside from positive AVA6000 updates.

Market information

SymbolPrimary exchanges


AVA6000 shows signs of successful tumour targetting
Lighthouse | 17 Jan 2023
Diagnostics business back into the spotlight
Update | 13 Dec 2022
Diagnostics M&A-led growth strategy is ready to Launch
Lighthouse | 18 Oct 2022

Recent News

Successful completion of fourth AVA6000 dose escalation
17 Jan 2023
Avacta to host Therapeutics Division Science Day
19 Dec 2022
Result of the Open Offer
08 Nov 2022
Avacta to present at Theranostics FAP summit
31 Oct 2022